These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 24148618)

  • 1. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 4. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
    Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
    Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
    Kim HS; Lee HS; Nam KH; Choi J; Kim WH
    Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypo-methylation mediates chromosomal instability in pancreatic NET.
    Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
    Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
    Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
    Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered telomeres in tumors with ATRX and DAXX mutations.
    Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
    Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
    Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
    Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
    Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
    Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
    Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.
    Hechtman JF; Klimstra DS; Nanjangud G; Frosina D; Shia J; Jungbluth AA
    Pancreas; 2019 Mar; 48(3):396-399. PubMed ID: 30747827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.